BNP Paribas Financial Markets Sells 15,610 Shares of Solventum Co. (NYSE:SOLV)

BNP Paribas Financial Markets lessened its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 8.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 175,783 shares of the company's stock after selling 15,610 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.10% of Solventum worth $12,256,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD acquired a new position in shares of Solventum during the 1st quarter valued at about $5,889,000. EverSource Wealth Advisors LLC acquired a new position in Solventum during the 1st quarter valued at $30,000. GAMMA Investing LLC acquired a new stake in Solventum in the 2nd quarter worth $74,000. Massmutual Trust Co. FSB ADV acquired a new position in shares of Solventum during the second quarter valued at about $34,000. Finally, DNB Asset Management AS bought a new stake in shares of Solventum in the second quarter valued at about $1,227,000.

Solventum Trading Up 0.7 %

NYSE:SOLV traded up $0.48 during mid-day trading on Monday, reaching $71.99. 970,342 shares of the company were exchanged, compared to its average volume of 1,684,932. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a fifty day moving average of $70.55 and a 200 day moving average of $62.58.

Analyst Ratings Changes

A number of research analysts recently commented on the company. The Goldman Sachs Group upped their target price on Solventum from $48.00 to $54.00 and gave the company a "sell" rating in a research note on Monday, August 12th. Stifel Nicolaus began coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 price target for the company. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a report on Monday, November 11th. Wolfe Research initiated coverage on Solventum in a report on Thursday, September 26th. They issued a "peer perform" rating for the company. Finally, Wells Fargo & Company lowered their price target on Solventum from $69.00 to $64.00 and set an "equal weight" rating on the stock in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.